Healio  |  August 26, 2019

“Today’s decision in the Oklahoma opioid trial against Johnson & Johnson sends an important message to every pharmaceutical company involved in opioid litigation,” Regina LaBelle, JD, program director for the Addiction and Public Policy Initiative at the O’Neill Institute for National and Global Health Law at Georgetown University, told Healio Primary Care. “That is, they will be held accountable for the role they played in marketing and distributing opioids, and they are expected to contribute to a solution.”

Read the article here.